World PulseNow
Newsletter

OrthoPediatrics stock price target lowered to $18 by Truist Securities

Investing.com•Friday, October 10, 2025 at 10:20:58 AM
NegativeFinancial Markets
OrthoPediatrics stock price target lowered to $18 by Truist Securities
Truist Securities has lowered its stock price target for OrthoPediatrics to $18, indicating a more cautious outlook for the company. This adjustment reflects concerns about the company's performance and market conditions, which could impact investor confidence and future growth prospects. It's important for stakeholders to stay informed as these changes can influence investment decisions and the overall market sentiment.
— Curated by the World Pulse Now AI Editorial System
Read Original

Was this article worth reading? Share it

Recommended Readings
OrthoPediatrics stock price target cut to $23 from $39 at BTIG
Investing.com11 hours ago
OrthoPediatrics stock price target cut to $23 from $39 at BTIG
NegativeFinancial Markets
OrthoPediatrics has seen its stock price target slashed from $39 to $23 by BTIG, indicating a significant shift in market expectations for the company. This adjustment reflects concerns about the company's future performance and could impact investor confidence. Such changes in stock price targets are crucial as they can influence trading decisions and overall market sentiment.
Read full article
via Investing.com
Truist Securities raises Deere stock price target to $609 on cyclical trough
Investing.com2 days ago
Truist Securities raises Deere stock price target to $609 on cyclical trough
PositiveFinancial Markets
Truist Securities has raised its price target for Deere's stock to $609, indicating a positive outlook for the company as it navigates through a cyclical trough. This adjustment reflects confidence in Deere's resilience and potential for growth, which is significant for investors looking for stability in the agricultural equipment sector.
Read full article
via Investing.com
Truist Securities reiterates Buy rating on Peloton stock, maintains $11 price target
Investing.com2 days ago
Truist Securities reiterates Buy rating on Peloton stock, maintains $11 price target
PositiveFinancial Markets
Truist Securities has reaffirmed its Buy rating on Peloton stock, maintaining a price target of $11. This is significant as it reflects confidence in Peloton's potential for recovery and growth in the competitive fitness market, especially as the company continues to innovate and adapt to changing consumer preferences.
Read full article
via Investing.com
Truist Securities initiates coverage on CommVault Systems stock with Buy rating
Investing.com2 days ago
Truist Securities initiates coverage on CommVault Systems stock with Buy rating
PositiveFinancial Markets
Truist Securities has started coverage on CommVault Systems, giving it a 'Buy' rating. This is significant as it indicates confidence in the company's potential for growth and profitability, which could attract more investors and positively impact the stock price.
Read full article
via Investing.com
Latest from Financial Markets
Tech, Media & Telecom Roundup: Market Talk
The Wall Street Journal31 minutes ago
Tech, Media & Telecom Roundup: Market Talk
NeutralFinancial Markets
In the latest Market Talks, insights are shared on BCE and the performance of European semiconductor companies, highlighting trends and developments in the technology, media, and telecom sectors. This information is crucial for investors and industry professionals looking to stay informed about market dynamics.
Read full article
via The Wall Street Journal
Playtika names Erez Hershkovitz as chief accounting officer
Investing.com40 minutes ago
Playtika names Erez Hershkovitz as chief accounting officer
PositiveFinancial Markets
Playtika has appointed Erez Hershkovitz as its new chief accounting officer, a move that signals the company's commitment to strong financial leadership. This appointment is significant as it comes at a time when Playtika is looking to enhance its financial strategies and operations, ensuring transparency and accountability in its financial reporting.
Read full article
via Investing.com
Lightbridge EVP Mushakov sells $628k in shares
Investing.com40 minutes ago
Lightbridge EVP Mushakov sells $628k in shares
PositiveFinancial Markets
Lightbridge's Executive Vice President, Mushakov, has sold $628,000 worth of shares, indicating confidence in the company's future. This move could signal positive developments ahead for Lightbridge, as executives often sell shares to diversify their portfolios or capitalize on favorable market conditions. Investors will be watching closely to see how this impacts the company's stock performance.
Read full article
via Investing.com
Nasty News? Until Now, the Markets Said All Was Well.
The New York Times40 minutes ago
Nasty News? Until Now, the Markets Said All Was Well.
NeutralFinancial Markets
The third quarter has been surprisingly positive for investors, even amidst various domestic and global challenges. This raises questions about whether this upward trend can continue or if the good times are coming to an end. Understanding these market dynamics is crucial for investors looking to navigate potential shifts.
Read full article
via The New York Times
Morgan Stanley Asks to Pull Cash From Jefferies’ Point Bonita
Bloomberg41 minutes ago
Morgan Stanley Asks to Pull Cash From Jefferies’ Point Bonita
NegativeFinancial Markets
Morgan Stanley is looking to withdraw funds from a Jefferies Financial Group investment due to concerns over its exposure to the bankrupt auto-parts supplier, First Brands Group. This move highlights the growing unease in the investment community regarding the stability of funds tied to struggling companies, which could signal broader implications for investors and the market.
Read full article
via Bloomberg
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants
Investing.com41 minutes ago
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants
PositiveFinancial Markets
Cellectar Biosciences has successfully raised $5.8 million through the exercise of warrants and the issuance of new inducement warrants. This funding is significant as it bolsters the company's financial position, allowing it to advance its innovative therapies in the biotechnology sector. The capital infusion not only supports ongoing research but also enhances investor confidence in Cellectar's future prospects.
Read full article
via Investing.com